Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Synthon Chooses Avacta’s Optim 1000 for High Throughput Formulation Studies

Published: Thursday, April 04, 2013
Last Updated: Thursday, April 04, 2013
Bookmark and Share
Pharmaceutical developers at Synthon, a global specialist in the development and manufacture of generic medicines, have chosen an Optim 1000 high throughput, micro-volume protein analysis system from Avacta for preliminary formulation studies.

Bas Kokke, Principal Scientist at Synthon, explained: “In recent years, our work has begun to focus on biopharmaceuticals and for that we needed different instrumentation to develop assays and study proteins in far more detail. After initial discussions with Avacta, we sent some samples for analysis and were impressed by the Company’s approach and responsiveness. As well as high throughput, a big advantage of the Optim 1000 is the small sample volume required – down to 9 µl – which is perfect for us. This is so important because we don’t want to make large quantities of each formulation when conducting fairly large, high throughput studies early on in a project.”
 
Guy de Roo, Lead Scientist at Synthon, added: “The Optim 1000 is now used for all formulation projects as an initial screening instrument and we regularly perform around 50 formulations for a given project, where we used to be restricted to 10 or 15. The melting point data from the Optim system has shown a good correlation with long term stability, and this is very valuable to us. The support we have had from Avacta has been excellent; they are very open and flexible and our work has really progressed.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Avacta Analytical Partners with UCL
Avacta Analytical is partnering with University College London (UCL) as an industrial sponsor of the EPSRC Centre for Innovative Manufacturing in Emergent Macromolecular Therapies.
Friday, November 18, 2011
Scientific News
Flu Vaccine May Reduce Risk of Death For Type 2 Diabetes Patients
Researchers at Imperial College London have suggested that the vaccine may have substantial benefits for patients with long-term conditions.
Flu Vaccine May Reduce Death Risk of Type 2 Diabetes
New research suggests that a new flu vaccine may reduce probability of type 2 diabetes patients being hospitalised with stroke and heart failure.
Disrupting Tumour-Promotion in Humans
Researchers have modified an existing protein to represses a specific cancer-promoting ‘message’ within cells.
Protein Nanocages Could Improve Drug Design and Delivery
HHMI scientists have designed and built 10 large protein icosahedra that are similar to viral capsids that carry viral DNA.
Vaccine Strategy Targets Multiple Influenza Viruses
Scientists have identified vaccine-induced antibodies that can neutralize strains of influenza virus that infect humans.
Antibody-Based Drug for Multiple Sclerosis
New antibody-based drug paves the way for new strategies for controlling and treating multiple sclerosis.
Structure of Cold Virus Solved
Researchers have identified the structure of an elusive cold virus linked to child asthma and respiratory infections, providing the foundation for treating the virus.
'Poison Pill' Fed to Deadly Virus
Researchers have created a genetic modification within a virus (with funny name), rendering it unable to replicate, mutate or cause illness.
World First Alzheimer's Vaccine Breakthrough
Researchers have made a breakthrough discovery towards an effective vaccine for Alzheimer's by targeting associated proteins.
Immunotherapy Drug Combo Targets Cancer
Mayo Clinic researchers identify potential immunotherapy drug combination that shows therapeutic effects against advanced and metastatic cancers.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!